Corcept Therapeutics' Chief Development Officer William Guyer sold 20,000 shares worth $1.9 million on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in November 2024. Despite liquidating 83% of his direct holdings, Guyer retains 130,000 stock options. The sale comes as Corcept achieved FDA approval for Lifyorli (cortisol-blocking ovarian cancer drug) ahead of schedule and raised full-year revenue guidance to $950 million-$1.05 billion, though the company posted a $31.8 million loss in Q1 due to heavy launch spending.

The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated biotech exposure with 30 holdings. The analysis concludes XPH is the more appealing long-term choice due to its lower fees and superior performance.

Pomerantz Law Firm has filed class action lawsuits against Corcept Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics. The primary case involves Corcept, which faced a 50.4% stock price decline after the FDA issued a Complete Response Letter for its relacorilant drug, citing insufficient evidence of effectiveness. Investors with losses are urged to contact the firm by the April 21, 2026 deadline to potentially serve as lead plaintiff.

A class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) alleging that company executives made materially false and misleading statements about the clinical trial strength and regulatory prospects of their drug relacorilant. The complaint claims defendants overstated the drug's approval chances while concealing known FDA concerns about insufficient clinical evidence supporting the New Drug Application.

A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its relacorilant drug candidate for Cushing's syndrome. The company claimed the clinical trials provided 'powerful support' for FDA approval, but the FDA issued a Complete Response Letter citing insufficient evidence of effectiveness. Corcept's stock plummeted 50.4% following the December 31, 2025 disclosure. Investors who purchased shares between October 31, 2024, and December 30, 2025, have until April 21, 2026, to apply as lead plaintiffs.

Hagens Berman is alerting Corcept Therapeutics (CORT) investors of an April 21, 2026 lead plaintiff deadline in a securities fraud class action. The lawsuit alleges Corcept concealed FDA warnings about insufficient clinical data for its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, causing CORT stock to crash 50% from $70.20 to $34.80, erasing $2.5 billion in market value.

Rosen Law Firm is alerting investors in Corcept Therapeutics (CORT) who suffered losses exceeding $100K to join a securities class action lawsuit before the April 21, 2026 deadline. The lawsuit alleges that Corcept misrepresented the strength of clinical trial data supporting its relacorilant drug application to the FDA, while concealing known material risks of non-approval. Similar class actions have been filed against Alight, Inc. and Soleno Therapeutics, Inc.

A class action lawsuit has been filed against Corcept Therapeutics Incorporated alleging that company executives made materially false and misleading statements about the clinical trial strength and regulatory prospects of their drug relacorilant. The lawsuit claims defendants overstated the drug's approval likelihood while the FDA had raised significant concerns about the clinical evidence supporting the New Drug Application. Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 are encouraged to join the case.

The Gross Law Firm announces a securities class action lawsuit against Corcept Therapeutics (CORT) for allegedly making false and misleading statements regarding FDA interactions and expectations for relacorilant NDA approval. The lawsuit covers the period from October 31, 2024 to December 30, 2025, with a lead plaintiff deadline of April 21, 2026. Shareholders who purchased CORT shares during this period are encouraged to register for potential recovery.

Hagens Berman alerts Corcept Therapeutics (CORT) investors of an April 21, 2026 lead plaintiff deadline in a securities fraud class action. The lawsuit alleges Corcept concealed FDA warnings about insufficient clinical data for its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, causing CORT stock to plummet 50% from $70.20 to $34.80, erasing $2.5 billion in market value.

A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its relacorilant drug candidate for Cushing's syndrome. The company claimed the clinical trials provided 'powerful support' for FDA approval, but the FDA issued a Complete Response Letter citing insufficient evidence of effectiveness. Corcept's stock plummeted 50.4% following the December 31, 2025 disclosure. Investors who purchased shares between October 31, 2024, and December 30, 2025, are eligible to participate in the lawsuit.

Levi & Korsinsky filed a class action securities lawsuit against Corcept Therapeutics for alleged fraud between October 31, 2024 and December 30, 2025. The complaint alleges that defendants made false statements about FDA interactions regarding relacorilant's NDA approval prospects, when the FDA had actually expressed concerns about the drug's effectiveness assessment program and the GRACE study design. Investors who suffered losses during this period can request lead plaintiff status by April 21, 2026.